Search results (66)
« Back to NewsThe latest news, stories and exciting findings from across the Oxford cancer research community
Professor Sarah Blagden shares cutting-edge precision prevention research at Oxford in new Channel 4 Documentary
21 November 2025
Over the past year, Professor Blagden has been filming for Cancer Detectives: Finding the Cures, a new three-part documentary series from Channel 4 which follows three scientists on the front lines of cancer research across the UK.
Oxford Oncology at ESMO 2025
4 November 2025
The European Society of Medical Oncology (ESMO) Annual Congress took place on 17th-21st October, showcasing the latest advances and insights from the global oncology community. As Europe’s largest oncology meeting, ESMO brings together thousands of researchers, clinicians, and industry leaders for an exchange of cutting-edge research and clinical innovation. Members of the Department of Oncology were in Berlin to present their research, chair sessions, and network with collaborators from across Europe and beyond. Below are some of the highlights from our department’s contributions to ESMO 2025.
Michael Bryan wins international award at Europe’s largest cancer conference
24 October 2025
Michael - who is a CRUK Oxford Centre DPhil in Cancer Science student, working in the Nuffield Department of Medicine's Centre of Immuno-oncology - has been awarded the Best Poster Prize in CNS Tumours at the 2025 European Society for Medical Oncology (ESMO) Congress.
Oxford Cancer Announces 2025 CRIS Cancer Clinical Career Fellows
13 October 2025
Oxford Cancer, together with the CRIS Cancer Foundation, is delighted to announce the appointment of the 2025 CRIS Cancer Postdoctoral Clinical Fellows: Dr Rebecca Ling and Dr Casmir Turnquist. Both Fellows will lead on two distinct projects focused on childhood cancer.
Dr Peter Wan Awarded Pancreatic Cancer UK Fellowship to Develop New Immunotherapy for Pancreatic Cancer
9 October 2025
Dr Peter Kok-Ting Wan, PhD, postdoctoral researcher at the Department of Oncology, has been awarded a prestigious fellowship from Pancreatic Cancer UK to develop a new immunotherapy for pancreatic cancer, which has the lowest survival rate of any common cancer
New ‘off-the-shelf’ immunotherapy shows promise for treating high-risk childhood leukaemia
3 September 2025
Scientists at the University of Oxford, together with colleagues at Imperial College London and the University of Glasgow, have developed a new type of immunotherapy that could improve outcomes for infants and children with high-risk leukaemia.
Action-packed day of immuno-oncology presentations, PPI and networking at this years' annual OCION Symposium!
16 June 2025
On 13th June 2025 we welcomed 180 members of the Oxford Cancer Immuno-Oncology Network to the Mathematical Institute in Oxford for our annual in-person Symposium.
Professor Andrew McMichael elected to the US National Academy of Sciences
6 May 2025
The National Academy of Sciences (NAS) in the US just announced the election of 120 members and 30 international members in recognition of their distinguished and continuing achievements in original research. Election to membership in the NAS is a mark of excellence in science and considered one of the highest honours that a scientist can receive.
New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes
23 April 2025
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
Dr David Church awarded Senior Cancer Research Fellowship from Cancer Research UK
21 March 2025
David’s research will focus on immune dysregulation in colorectal and endometrial pre-cancers and cancers.
OCION: In conversation with Tamsin Cargill
28 February 2025
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with OCION Pump Prime awardee - Dr. Tamsin Cargill - to discuss her research.
Pancreatic cancer immune map provides clues for precision treatment targeting
6 February 2025
New research - published today in Nature Communications - shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
Predicting Response to Rectal Cancer Treatment through the S:CORT consortium
5 December 2024
Recent research from the S:CORT team spanning three publications has identified key biomarkers and treatment strategies that predict and enhance effectiveness of radiotherapy in rectal cancer treatment.
OCION: In conversation with Adán Pinto-Fernández
3 December 2024
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Dr. Adán Pinto-Fernández to discuss his research.
University of Oxford unveils new vaccine development partnership
15 November 2024
Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian Biotech Innovator, Univercells.
2024 OCION Pump Prime Awardees Named
14 November 2024
Congratulations to the 2024 OCION Pump Prime Awardees, funded by the CRUK Oxford Centre and NIHR Oxford BRC
COMBATcancer at the HIPP Summer School 2024
1 November 2024
Aleksandra Dzhoneva - Postdoctoral Scientist- shares her experience at the HIPP Summer School 2024, which she attended to present research as part of the COMBATcancer consortium. Her attendance was fully funded by Oxford Cancer.
Dr Bo Sun awarded Future Leaders Grant
15 October 2024
The three-year £225,000 grant from The Brain Tumour Charity will fund research into whether it's possible to use T-cells to track and detect gliomas.
OCION: In conversation with Alfred Zippelius
7 October 2024
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Alfred Zippelius to discuss his research.
OCION: In conversation with Ignacio Melero
11 September 2024
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Ignacio Melero to discuss his research.